Sol-Gel completes patient visits in Phase 3 SGT-610 trial for Gorlin syndrome

• Sol-Gel Technologies reached last patient last visit in its pivotal Phase 3 trial of SGT-610 for Gorlin syndrome.
• Top-line results have not been presented; release remains scheduled for late November 2026.
• The study is designed to show whether SGT-610 can prevent new basal cell carcinoma lesions on the face.
• Next steps include database lock, statistical analysis, then a readout that could shape regulatory and commercialization plans.
• The blinded, vehicle-controlled trial enrolled 113 patients; 102 completed 12 months of treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004537), on September 17, 2026, and is solely responsible for the information contained therein.